Can a cancer drug help flush out hidden HIV?
NCT ID NCT05187429
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a single low dose of nivolumab, a drug used in cancer immunotherapy, can reduce the latent HIV reservoir in people living with HIV who are on antiretroviral therapy (ART). The latent reservoir is a group of dormant HIV-infected cells that current treatments cannot eliminate, forcing lifelong ART. The trial enrolls 42 adults with well-controlled HIV and will first test safety, then randomly assign some participants to receive nivolumab or a placebo to measure effects on the reservoir.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo)
What this could lead to
If successful, this could point toward a way to reduce the hidden HIV reservoir, potentially allowing people with HIV to stop antiretroviral therapy without the virus rebounding.
What could go wrong
This is an early Phase 1/2 trial with only 42 participants, so results are preliminary. Nivolumab can cause immune-related side effects, and it is unknown if a single low dose will have any lasting effect on the reservoir.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV I INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Hospital - Department of Infecious Diseases
RECRUITINGMelbourne, Victoria, 3181, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tan Tock Seng Hospital
RECRUITINGSingapore, 308433, Singapore
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••